Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638307 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A Phase 1 study of Advanced Breast Cancer, sponsored by Stemline Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06638307 is a Phase 1 study of Advanced Breast Cancer that is actively recruiting participants, run by Stemline Therapeutics. The registered enrollment target is 240 participants, below the 456-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06638307, a Phase 1 study of Advanced Breast Cancer, is actively recruiting participants, sponsored by Stemline Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Conditions Studied
Interventions
- DRUG Elacestrant
- DRUG MEN2312
Study Locations (20)
Florida
- Advent Health Orlando - Altamonte Springs
- Sarah Cannon Research Institute at Florida Cancer Specialists - Orlando
- Florida Cancer Specialists & Research Institute (FCS) - Sarasota - Sarasota
- Moffitt Cancer Center - Tampa
California
- UC San Diego Moores Cancer Center - La Jolla
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
- UCLA Hematology Oncology - Parkside - Santa Monica
New York
- Perlmutter Cancer Center - Sunset Park - Brooklyn
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
Arkansas
- Highlands Oncology Group - Springdale
Connecticut
- Yale Comprehensive Cancer Center - New Haven
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06638307
The ClinicalTrials.gov registry entry for NCT06638307 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 456-participant average among 28 other Advanced Breast Cancer trials with a reported enrollment target (47% lower). The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Elacestrant is the first listed.
NCT06638307 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06638307 about?
NCT06638307 is a clinical study titled "A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer". This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
What is the current status of trial NCT06638307?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-10-25. Estimated completion is 2026-10.
What conditions does trial NCT06638307 study?
This clinical trial studies the following conditions: Advanced Breast Cancer.
What interventions are being tested in trial NCT06638307?
The interventions under investigation include: Elacestrant (DRUG), MEN2312 (DRUG).
Who is sponsoring clinical trial NCT06638307?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638307 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.